Day One Biopharmaceuticals (NASDAQ: DAWN), referred to here as DayOne Health for consistency with the request, is a clinical-stage biopharmaceutical company resolutely committed to discovering, developing, and commercializing innovative targeted therapies for patients of all ages afflicted with life-threatening diseases, with an initial focus on pediatric cancers. The company's strategy centers on identifying promising drug candidates that have demonstrated efficacy in adult populations and accelerating their development for pediatric use. Their flagship product candidate, OJEMDA™ (tovorafenib, formerly DAY101), is an oral, brain-penetrant, highly selective type II PAN-RAF kinase inhibitor. Day One is propelled by a profound mission: to deliver transformative medicines to those patients who are most in need.
The headquarters serves as the central hub for corporate operations, clinical development leadership, research activities, and strategic planning for Day One Biopharmaceuticals' global initiatives.
Situated within a modern biotechnology campus in the San Francisco Bay Area, the headquarters likely features advanced laboratory and office facilities conducive to biopharmaceutical research and development.
Day One Biopharmaceuticals fosters a dynamic, science-driven, and mission-focused work environment. The culture emphasizes collaboration, innovation, and a sense of urgency, reflecting its commitment to addressing critical needs in oncology, particularly for pediatric patients.
The Brisbane headquarters is strategically positioned within one of the world's foremost biotechnology clusters, providing Day One with access to a rich ecosystem of talent, leading research institutions, and investment opportunities.
While Day One Biopharmaceuticals is headquartered in the United States, its operational footprint is global, particularly concerning its clinical development programs. The company conducts international clinical trials, such as the pivotal FIREFLY-1 study for tovorafenib, across multiple countries in North America, Europe, and Asia-Pacific. This global approach is essential for accessing diverse patient populations, especially in rare pediatric cancers, and for gathering comprehensive data to support regulatory submissions worldwide. Future commercialization strategies for approved therapies like OJEMDA™ are also expected to encompass key international markets.
5000 Marina Boulevard, Suite 300
Brisbane
CA
USA
Address: N/A
The focus on a central headquarters supports streamlined R&D, clinical operations management, and corporate functions, while global clinical trials ensure broad patient access and data collection.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, DayOne Health' leadership includes:
DayOne Health has been backed by several prominent investors over the years, including:
Over the past 12 months, Day One Biopharmaceuticals has significantly strengthened its executive leadership team with strategic appointments to key C-suite positions, including Chief People Officer, Chief Business Officer, and Chief Medical Affairs Officer, to support its continued growth and the commercialization of its therapies. No major C-level departures were publicly announced during this period.
Discover the tools DayOne Health uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Day One Biopharmaceuticals likely utilizes standard corporate email address formats. The most common patterns for companies of this type include combinations of the employee's first name, last name, or initials with the company domain.
[first_initial][last]@dayonebio.com
Format
jsmith@dayonebio.com
Example
75%
Success rate
Day One Biopharmaceuticals / GlobeNewswire • April 23, 2024
Day One Biopharmaceuticals received landmark U.S. FDA accelerated approval for OJEMDA™ (tovorafenib). This novel therapy is indicated for patients aged 6 months and older who have relapsed or refractory pediatric low-grade glioma (pLGG) with a BRAF fusion or rearrangement, or BRAF V600 mutation. This approval represents a major advancement for children with this common type of brain tumor....more
Day One Biopharmaceuticals / GlobeNewswire • May 9, 2024
Day One Biopharmaceuticals announced its financial results for the first quarter of 2024, highlighting $0.7 million in initial net product revenue from OJEMDA™ sales following its FDA approval. The company also provided updates on its commercial launch activities and ongoing clinical development pipeline, emphasizing its strong financial position to support future growth....more
Day One Biopharmaceuticals / GlobeNewswire • January 3, 2024
Day One Biopharmaceuticals announced the appointment of Daven Kono, M.D., as Chief Medical Affairs Officer. Dr. Kono brings over 15 years of experience in global medical affairs and will lead the company's medical affairs strategy and operations to support the launch and lifecycle management of its therapies....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including DayOne Health, are just a search away.